- Home
- / DICE Therapeutics
DICE Therapeutics
Stock Price
$47.5
2023-08-18
Market Capitalization
$2.3 B
2023-08-18
Revenue
$1.1 M
FY, 2021
DICE Therapeutics Summary
Company Summary
- Overview
- DICE Therapeutics (formerly known as DiCE Molecules) is a biotech company developing therapies in immunology for patients with chronic diseases. It offers an orally bioavailable Interleukin-17 (IL-17) antagonist for the treatment of psoriasis. The company also researches the alpha 4 beta 7 (α4ß7), alpha V beta 1 (αVß1), and alpha V beta 6 (αVß6) integrin antagonist programs.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- South San Francisco, CA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Scott Robertson, Chief Business & Financial Officer
Tim Lu, Chief Medical Officer
John Jacobsen, Chief Scientific Officer
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
279 E. Grand Avenue, Suite 300
DICE Therapeutics Financials
Summary Financials
- Net income (Q2, 2023)
- ($34.8M)
- Cash (Q2, 2023)
- $73.5M
- EBIT (Q2, 2023)
- ($39.5M)
- Enterprise value
- $2.2B